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Drug delivery systems containing gentamicin were studied as a treatment against experimental brucellosis
in mice. Micro- and nanoparticles prepared by using poly(D,L-lactide-coglycolide) (PLGA) 502H and micro-
particles made of PLGA 75:25H were successfully delivered to the liver and the spleen, the target organs for
Brucella melitensis. Both polymers have the same molecular weight but have different lactic acid/glycolic acid
ratios. Microparticles of PLGA 502H and 75:25H released their contents in a sustained manner, in contrast to
PLGA 502H nanoparticles, which were degraded almost completely during the first week postadministration.
The values of the pharmacokinetic parameters after administration of a single intravenous dose of 1.5 mg/kg
of body weight of loaded gentamicin revealed higher areas under the curve (AUCs) for the liver and the spleen
and increased mean retention times (MRTs) compared to those for the free drug, indicating the successful
uptake by phagocytic cells in both organs and the controlled release of the antibiotic. Both gentamicin-loaded
PLGA 502H and 75:25H microparticles presented similar pharmacokinetic parameter values for the liver, but
those made of PLGA 75:25 H were more effective in targeting the antibiotic to the spleen (higher AUCs and
MRTs). The administration of three doses of 1.5 mg/kg significantly reduced the load associated with the
splenic B. melitensis infection. Thus, the formulation made with the 75:25H polymer was more effective than
that made with 502H microspheres (1.45-log and 0.45-log reductions, respectively, at 3 weeks posttreatment).
Therefore, both, pharmacokinetic and pharmacodynamic parameters showed the suitability of 75:25H micro-
spheres to reduce the infection of experimentally infected mice with B. melitensis.
Brucellosis remains a major zoonosis worldwide (17), and it
is among the microorganisms most likely to be used as biolog-
ical weapons (24). Specific therapy reduces morbidity, shortens
the duration of illness, and decreases the incidence of compli-
cations (31); however, relapse currently presents a significant
problem (27). Long-lasting combined drug treatments are dif-
ficult to achieve (27); and also the intracellular location of the
pathogen in phagocytic cells, mainly in the liver and the spleen,
are involved in therapeutic failure (22). Drug delivery systems
containing gentamicin (GEN) have been developed as poten-
tial alternatives to classical therapy, and the usefulness of these
vectors has been shown (5, 7, 10, 23, 30). Although GEN is
effective against the pathogen in vitro (11, 18, 25), it shows a
low level of intracellular penetration due to its polar nature;
hence, its entrapment in particulate carriers might facilitate
the entrance of the drug into the cells. Moreover, sustained
drug delivery could avoid long-term treatment, eliminating the
toxic systemic levels achieved during classical antibiotic ther-
apy with the free drug. Despite the promising results obtained
with GEN-containing liposomes (7, 10, 30), important draw-
backs are attributed to these vesicles. Their instability in the
presence of blood lipoproteins and their osmotic fragility can
destabilize them, leading to leakage of the entrapped drug.
Additionally, problems with their long-lasting stability upon
storage remain (3, 6). On the other hand, microspheres were
suitable a priori for this aim because of their higher stability
and capture by mononuclear phagocytes, the niche of Brucella
(23); in fact, microspheres obtained by spray drying produced
a significant reduction of splenic infection in mice (21, 22).
However, some of the animals died of pulmonary embolism
after the administration of multiple doses, with death being
attributed to the higher levels of aggregation of the particles
(22). Therefore, the aim of the present work was to change the
preparation method to obtain more suitable formulations and
also, for the first time, to manufacture and study the effects of
GEN-containing nanoparticles.
The in vivo fates of these micro- and nanoparticles of dif-
ferent poly(D,L-lactide-coglycolide) (PLGA) copolymers were
studied. Finally, the distribution and degradation of particles,
as well as pharmacokinetics and pharmacodynamics of encap-
sulated GEN, were determined. The results demonstrated
their therapeutic efficacy against Brucella melitensis infections
in mice.
MATERIALS AND METHODS
Materials. GEN sulfate, rhodamine B isothiocyanate, and lecithin (L-phos-
phatidylcholine) were from Sigma-Aldrich Co. (St. Louis, MO). PLGA copoly-
mer with a free carboxyl end group of 13.7-kDa PLGA 50:50 (Resomer RG
502H) was provided by Boehringer-Ingelheim (Ingelheim, Germany), and PLGA
75:25 25 kDa (75/25 ratio of the D and L forms; 2.5 Å; 75:25H) was obtained from
Alkermes (Wilmington, DE). Monopotassium phosphate, sodium dibasic phos-
phate, sodium hydroxide, trichloroacetic acid, and dichloromethane were from
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Panreac (Barcelona, Spain). Polyvinyl alcohol (PVA; molecular weight, 15,000)
was purchased from BDH Supplies (Poole, United Kingdom). Pentafluoropro-
pionic acid was from Fluka Chemie (Buchs, Switzerland). Tobramycin (internal
standard), procured as Tobra-Gobens (the brand name of the product registered
for clinical use in Spain), was purchased from Normon (Madrid, Spain). Meth-
anol (high-pressure liquid chromatography [HPLC] grade) was from Merck
(Darmstadt, Germany). For bacterial growth Trypticase soy broth was purchased
by bioMe´rieux (Marcy l’Etoile, France), and American bacteriological agar was
from Pronadisa (Madrid, Spain).
Preparation of gentamicin-containing formulations. Poly(lactide-coglycolide)
formulations containing GEN were prepared by a water (W)-oil (O)-water sol-
vent evaporation technique (2). Briefly, the antibiotic dissolved in 0.5% PVA in
phosphate buffer (pH 6.0) and 200 mg of either 502H or 75:25H copolymers
(dissolved either in dichloromethane for microspheres or in ethyl acetate for
nanoparticles) were mixed by ultrasonication (sonifier 450; Branson Ultrasonics
Corp., Danbury, CT) under cooling for 1 min to form a W1-O emulsion. For
fluorescent formulations, rhodamine B isothiocyanate (0.5 mg/ml) was added to
the inner aqueous phase together with GEN. This inner emulsion was added to
2 ml 1% PVA (W2), and the mixture was homogenized by ultrasonication. The
resulting (W1-O)W2 emulsion was poured into 50 ml of 0.2% PVA, and the
mixture was continuously stirred for 3 h at room temperature to allow solvent
evaporation and particle formation. After their preparation, the particulate car-
riers were isolated by centrifugation (at 7,000 g for 5 min for microspheres and
at 12,000  g for 30 min for nanospheres), washed three times with ultrapure
water, and freeze-dried.
Particle characterization. The sizes of the microspheres loaded with rhoda-
mine were analyzed by light microscopy (BH-2 microscope; Olympus, Spain) and
by laser diffractometry (Mastersizer, Malvern Instruments, United Kingdom) of
the microparticles without the fluorescent marker. For the latter, a small amount
was dispersed in water and analyzed under continuous stirring, and the average
particle size was expressed as the mean volume diameter (in micrometers). The
size and polydispersion of the fluorescent nanoparticles were determined by
photon correlation spectroscopy with a Zetamaster analyzer system (Malvern
Instruments).
Gentamicin loading of PLGA micro- and nanoparticles. Briefly, a known
amount of the loaded particles was dispersed in 1 ml of 0.1 N NaOH, the samples
were centrifuged (25,000  g, 15 min), and the GEN in the supernatants was
quantified by HPLC-mass spectrometry (14).
In vivo studies. Female BALB/c mice (weight, 20  1 g) were supplied by
Harlan Iterfauna Ibe´rica (Barcelona, Spain). The experiments were performed
in compliance with the regulations of the responsible committee of the Univer-
sity of Navarra, in line with the European legislation on animal experiments
(86/609/EU).
(i) Distribution and degradation of formulations in vivo. PLGA particle up-
take by the liver and the spleen, the two main target organs of Brucella organ-
isms, was studied in mice. Two milligrams of fluorescent particulate carriers was
intravenously administered in 0.2 ml of freshly reconstituted 1% lecithin in sterile
saline (19). At different times postadministration (4 h, 1 week, and 2 weeks), the
animals were killed, the liver and the spleen were embedded in a tissue-process-
ing medium (O.C.T., Sakura, The Netherlands), immersed in melted isopentane
(Fluka, Buch, Switzerland), and stored at 20°C. The tissue samples were cut
into 5-m sections in a cryostat (2800 Frigocut E; Reichert-Jung, Germany) and
were finally visualized by fluorescence microscopy (26).
(ii) Pharmacokinetic studies. In order to perform comparisons of the phar-
macokinetics of free and loaded GEN, mice (n  3) received one dose of 30 g
(1.5 mg/kg of body weight) of the antibiotic intravenously either free or loaded
into PLGA particles. For calculation of the values of the pharmacokinetic pa-
rameters for free antibiotic, higher concentrations had to be administered (three
doses of 40 mg/kg of GEN every 2.5 h), and the data were further normalized to
the administered doses. At different times (5, 6, 7, 9, 10, 24, and 96 h for free
gentamicin; 1, 2, 4, 7, 14, and 28 days for the PLGA formulations), the animals
were anesthetized, bled by retroorbital puncture, and killed by cervical disloca-
tion; and the organs (spleen, liver, and kidneys) were removed. Once the organs
were diluted in saline solution, they were homogenized and centrifuged (10,000 g,
15 min), and the supernatants were collected. Proteins were precipitated by 1%
trichloroacetic acid, and the samples were analyzed by HPLC, as described
previously (14).
The values of the pharmacokinetic parameters for GEN were determined by
using compartmental and noncompartmental analyses. The concentration-ver-
sus-time profiles for each tissue were described by compartmental models, as-
suming first-order distribution rate constants between the plasma and the liver,
spleen, or kidney. GEN showed a two-exponential distribution for the spleen, as
can be seen by examination of the raw tissue concentration-versus-time data. In
order to describe this phenomenon properly, a model describing the distribution
of GEN from plasma to the tissues by the use of two first-order distribution rate
constants, one of which was slower, was fitted to the data. With respect to the
liver and kidneys, a simpler model was fitted to the data.
The values of the various pharmacokinetic parameters, such as clearance,
disposition half-life, and the accumulation rate (maximum concentration in se-
rum [Cmax]/area under the concentration-time curve [AUC]), were calculated
from the estimated parameters by standard procedures. All the analyses were
performed with the WinNonlin, version 1.5, computer program (Scientific Con-
sulting, Inc.).
To select the best pharmacokinetic model, a number of criteria, including the
Akaike information criterion, the Schwartz criterion, and the F test, were used.
In addition, the visual inspection of the residual plots and the calculated coef-
ficients of variation of the pharmacokinetic parameter estimates were also used
as a guide in selecting the best model. Coefficients of variation lower than 50%
were considered acceptable.
The area under the plasma concentration-time curve and the mean residence
time (MRT) were determined by use of the linear trapezoidal rule. The times
during which the antibiotic concentrations exceeded the minimal bactericidal
concentration (MBC) for Brucella were also determined for the liver and the
spleen.
Experimental Brucella infection in mice and treatment with encapsulated
gentamicin. BALB/c mice and the reference strain B. melitenis 16 M (biotype 1)
were used for the experimental infection study. For animal infection, isolated
colonies of the bacteria were inoculated in Trypticase soy broth medium and
incubated at 37°C under shaking to the exponential growth phase. A washed
suspension of the bacterial pellet was diluted in sterile saline solution to obtain
the corresponding infective dose.
Mice were infected intraperitoneally with B. melitensis 16 M (1  105 CFU/
mouse) to induce a chronic infection (8). After 2 weeks, the animals (n  6)
received different treatments: (i) GEN-loaded microspheres, (ii) empty formu-
lations, (iii) free GEN, or (iv) no treatment (control group). Three doses of free
or encapsulated GEN of 1.5 mg/kg were administered at days 14, 17, and 21
postinfection. At 8 days and 3 weeks after administration of the last dose, the
animals were killed, and the spleens (the target organs in murine brucellosis)
were extracted and homogenized. Appropriate dilutions were plated on Trypti-
case soy agar medium, and the number of colonies was determined after incu-
bation for 3 to 4 days at 37°C.
Statistical analysis. Student’s t test was performed for parametric studies and
a comparison of the results between two samples. For a comparison of the results
among three or more groups, one-way analysis of variance and the post-hoc
Tukey B test was performed for homoscedastic groups. The Tamhane test was
carried out for heteroscedastic groups. For nonparametric studies, the Mann-
Whitney U test was performed. Statistical significance levels were defined as P
values of 0.05 and 0.01.
RESULTS
Particle characterization. Microparticles formulated with
502H presented the highest loadings (11.9 g GEN/mg poly-
mer), followed by those formulated with 75:25H (8.3 g
GEN/g polymer), with mean diameters of 1.84  0.70 m
and 2.5  0.17 m, respectively. GEN-loaded nanoparticles
showed an average size of 310  2.00 nm, with a loading of 6.2
g GEN/mg of polymer.
Distribution of particles and degradation studies in vivo.
The optimal formulation should target to a high extent the
antibiotic in the organs harboring the pathogen, and after-
wards, a sustained release would be desired. Therefore, bio-
distribution studies were carried out to compare the particle
uptakes by phagocytic cells of the liver and the spleen and their
degradation rates. The particles were then labeled with rhoda-
mine so that they could be fluorescently quantified in both
organs. All particulate carriers were already taken up by both
organs 4 h after administration (Fig. 1). PLGA 502H formu-
lated in micro- or nanoparticles was taken up to a higher extent
by the liver (P  0.01), while the uptakes of the particles
formulated with 75:25H were similar in both organs. One week
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after particle administration, most of the nanoparticles had
already been degraded in both organs (more than 95%); this
resulted in statistical differences with respect to the degrada-
tion results for the microparticles (P  0.01). Finally, after 2
weeks, microparticles of the 502H formulation disappeared
almost completely (96%) from both organs, while the 75:25H
microparticles had been degraded by only 30% in the spleen.
The practical disappearance of nanoparticles within 1 week
from both organs made this formulation unsuitable for treat-
ment for brucellosis, since a sustained release is required;
therefore, it will be not be used in further studies.
Pharmacokinetic studies. Mice (n 3) were inoculated with
GEN (one dose of 30 g, 1.5 mg/kg) intravenously either in
free solution or encapsulated in 75:25H or 502H micropar-
ticles; and the concentrations of the antibiotic in the liver and
spleen (the target organs of Brucella infection) and kidney (as
a nephrotoxicity marker) were determined. In order to deter-
mine the pharmacokinetic parameters, it was necessary to ad-
minister three doses of free GEN (40 mg/kg every 2.5 h),
whereas just a single dose of GEN encapsulated in micropar-
ticles (1.5 mg/kg) had to be administered. The results indicated
that no antibiotic was detected in any of the organs studied 4
days after the administration of free GEN. The effects of the
encapsulation of GEN on the distribution of the drug are
shown in Fig. 2 and are summarized in Table 1, which show the
raw concentration-versus-time profiles (depicted with symbols)
for each tissue from the prediction model. The predicted val-
ues were adjusted to the real ones, indicating the adequacy of
the model in describing the kinetics of GEN in each tissue after
502H and 75:25H microsphere administration. In addition, the
pharmacokinetic parameters were accurately estimated (coef-
ficient of variation, 50%) (Table 1) and indicated that when
GEN was administered in free solution, GEN levels decreased
rapidly within the first 2 days postadministration. In contrast,
when GEN was administered in the encapsulated form, the
antibiotic concentrations in the three organs were high (above
the MBC), even after 28 days. Furthermore, encapsulation in
502H or 75:25H microparticles redirected the antibiotic to
both the liver and the spleen and substantially reduced the
level of drug accumulation in the kidneys. The increase in the
level of antibiotic accumulation was most pronounced in the
spleens, in which 502H and 75:25H microparticles increased
the AUC by 447- and 800-fold, respectively. In the liver, the
factors were 406-fold for 502H microspheres and 370-fold
for the 75:25H formulation. On the contrary, the GEN concen-
tration in the kidneys after microparticle administration was
significantly lower than that observed in the other organs.
The sustained-release properties of the PLGA micropar-
ticles were also reflected in the GEN pharmacokinetic param-
eters obtained, which showed lower Cmax values and longer
times to Cmax (Tmax) and MRTs in all tissues evaluated com-
pared with those obtained after administration of the free
antibiotic. Thus, free GEN disappeared very quickly from the
liver and the spleen, showing mean residence times of about
0.5 h. Finally, microspheres presented the highest MRT values
in the spleen (45 days for the 502H polymer and 60 days for
75:25H).
Similar concentration profiles were observed for both for-
mulations in the liver: on day 4 postadministration, similar
plateaus were achieved for both formulations (0.53 g/g for
75:25H and 0.65 g/g for 502H) (P  0.05), with AUC values
of 14.0 g  day/g for the 502H microspheres and 12.7
g  day/g for the 72:25H microspheres (P  0.05) (Fig. 2). In
contrast, the parameter estimated for the spleen showed con-
siderable differences between formulations, with the AUC val-
ues for the 75:25H microparticles (22.4 g  day/g) being sig-
nificantly higher than those for the 502H microparticles (12.5
g  day/g) (P  0.01). After a peak on day 1 postadministra-
tion (1.2 g/g for 75:25H particles and 0.99 g/g for 502H
particles; P  0.05), the drug concentration decreased to a
plateau of 0.45 g/g for the 75:25H microspheres and 0.35 g/g
(P  0.05) for the 502H formulation.
The MIC and MBC of GEN for Brucella were 0.25 and 0.5
g/ml, respectively (14). The time during which the antibiotic
concentrations exceeded the MBC in the spleen was similar
over time for the two selected formulations, but GEN re-
mained in the liver longer when it was administered in 502H
microspheres (14 day) than in the 75:25H formulation (6.1
days).
FIG. 1. Biodistribution of particles containing gentamicin in livers and spleens of treated mice at 4 h, 1 week, and 2 weeks postadministration
(2 mg of fluorescent particulate carriers was administered intravenously).
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Protective effect of microspheres containing gentamicin
against Brucella melitensis infection in mice. Under these ex-
perimental conditions, mice were infected with B. melitensis
and the treatment was started 2 weeks later. The results indi-
cated that neither the empty formulations nor free GEN pro-
duced any bactericidal effect. In contrast, both microsphere
formulations showed bactericidal effects during the two studies
(Table 2). After 1 week from the time of last administration of
the dose, the 75:25H microspheres were more effective than
those made of PLGA 502H in reducing the B. melitensis load
in the spleen. They achieved a 0.72-log reduction, while for the
502H microparticles, the reduction was 0.41 log; both of these
values are statistically different from the results achieved for
the negative control. At 3 weeks postinfection, the 502H for-
mulation did not improve the therapeutic activity (0.45-log
decrease). On the contrary, 75:25H was able to reduce the
Brucella infection level by 1.45 log units (range, 0.38 to 4.01 log
units of protection in individual animals).
DISCUSSION
Intracellular bacterial infections still constitute a challenge
for classical antimicrobial therapies due to the limited pene-
tration of active antibiotics. Thus, gentamicin is very active in
vitro against intracellular bacteria, such as Brucella melitensis,
but it is not effective in vivo due to its poor intracellular
penetration and inactivation by lysosomal enzymes (12). The
development of gentamicin delivery systems capable of intra-
cellular delivery has been described previously (22, 30). Nev-
ertheless, drawbacks like the osmotic fragility of liposomes
(20) and aggregation and embolism induction of microspheres
(22) suggested the need for the development of new formula-
tions of micro- and nanoparticles prepared with different co-
polymers of PLGA; however, on the basis of physicochemical
properties, adequate drug loading, and the capability to inter-
act with Brucella host cells to promote their oxidative burst
(15), three formulations were selected: micro and nanopar-
ticles of 502H and microparticles of 75:25H. Here we report
the results of the in vivo and in-cell behaviors obtained with
these formulations.
On the subject of the particle distribution in vivo, it was
interesting to study the fate and permanence of particles after
administration by looking for them at a similar location as the
Brucella organisms. After invasion, the organism multiplies in
regional lymph nodes, draining the site of entry, the spleen and
the liver. In fact, an enlarged spleen and an enlarged liver are
usual features during brucellosis. Some differences in particle
distribution were observed after their uptake by the spleen and
the liver, depending on the polymer type. Microspheres pre-
pared with PLGA 75:25H showed a similar distribution in both
organs, while for the 502H polymer the liver was the preferred
organ, regardless of the particle size, since both nano- and
microspheres showed the same distribution patterns. These
results suggest that hydrophilicity may play a role in the fate of
particles and their distribution to the liver, while for the more
hydrophobic polymer, no differential distribution to the two
organs was observed. The general rule is that hydrophilic sur-
faces decrease macrophage uptake and enhance the outcome
for the liver. In contrast, particle degradation and, therefore,
antibiotic release seem to depend on several factors, such as
the polymer used and the particle size. Several authors have
reported that as the glycolic acid content decreases, the rate of
degradation also diminishes (1, 13, 16), which is in agreement
with our results. The more hydrophobic 75:25H copolymer
presented a more sustained release, with only 30% degrada-
tion in splenic tissues at 2 weeks postadministration of the
particles, whereas the PLGA 502H particles were degraded
more than 96% over the same time. On the other hand, par-
ticle size is an important parameter that could affect the deg-
FIG. 2. Predicted and observed GEN concentrations (n 3) (g/g)
in spleen, liver, and kidney after administration of three doses of 40
mg/kg of free GEN or one dose of 1.5 mg/kg of microparticle-loaded
antibiotic and mean  standard deviation (n  3) of the observed
concentration of loaded GEN.
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radation of the PLGA matrix. As the particle size is reduced,
the surface area-to-volume ratio increases, resulting in a larger
surface area available for the autocatalytic hydrolysis of the
ester bonds of the PLGA polymer. Thus, under our experi-
mental conditions, the PLGA 502H nanospheres were de-
graded within the first week postadministration, while micro-
spheres of the same polymer were still in the liver and the
spleen for 2 weeks. The sustained release of the antibiotic is
extremely desirable for treatment for brucellosis, since sus-
tained release could reduce the duration of treatment and,
hence, facilitate the effectiveness of treatment. Therefore,
nanospheres were discarded because of their rapid elimination
from the target organs.
Determination of the efficiency of the particles for the tar-
geting of GEN in vivo was completed by the performance of
pharmacokinetic studies, and at the same time, the correlation
between pharmacokinetic parameters and the effectiveness of
the formulation for elimination of Brucella from the spleen
was assessed. The pharmacokinetic parameters illustrated the
markedly altered distribution of GEN-loaded PLGA com-
pared to that of the free drug, with higher concentrations of
GEN observed in the spleen and the liver when it was admin-
istered loaded in microspheres. At the same time, serum sam-
ples had undetectable concentrations. Taken together, these
results make evident the microparticle removal from the cir-
culation and accumulation primarily in the liver and the spleen,
precluding drug accumulation in the kidneys, where tubular
necrosis may occur in a concentration-dependent manner (13).
Although higher AUC values were obtained for the kidney
after GEN-loaded PLGA administration, this could not be
attributed to microsphere accumulation in this organ but was
the result of the continuous release of antibiotic from the
formulations after their accumulation in the liver and the
spleen, as assessed in a previous study (22). In fact, the rate of
gentamicin accumulation in the kidneys after free gentamicin
administration was 10-fold greater than that obtained after
administration of GEN-loaded PLGA, with absolute Cmax val-
ues 24-fold greater than the values observed in the kidney after
PLGA microparticle administration.
MRT and AUC values were sustained for both the 502H and
the 75:25H formulations compared to those for free GEN,
confirming the sustained release of the microencapsulated an-
tibiotic. By comparison of the two formulations, the highest
MRT and AUC values were observed for the 75:25H particles,
consistent with the lower level of degradation of this polymer
in the spleen.
As discussed above, distribution studies showed that at 2
weeks postadministration, 75:25H microspheres were observed
mainly in the spleen and, in discrete quantities, in the liver.
However, GEN was detected up to 4 weeks postadministration
in both the liver and the spleen. This long persistence of the
drug beyond the half-life of the vector could be expected, since
TABLE 1. Mean pharmacokinetic parameters of free or microsphere-loaded GEN in mice
Dosage form Organ Half-life(days) Tmax (days) Cmax (g/g)
a AUC (g  day/g)a Cmax/AUC (h1)a MRT (days)
Free GEN Liver 0.2 0.1 0.1  0.1 1.4  0.2 1.2 0.0 1.2  0.2 0.6  0.1
Spleen 0.37 0.1 0.1 0.1 1.9  0.0 0.9 0.1 2.1  0.3 0.6  0.1
Kidney 0.2 0.19 0.1 0.0 16.6  7.1 15.0 4.2 1.1  0.2 2.5  1.3
502H MPb Liver 14.5 7.6 7.3 1.6 25.1  2.7 468.3 58.7 0.05  0.01 13.7  0.4
Spleen NDc 0.9  0.1 33.3  5.7 416.0 168 0.08  0.02 45.0  5.15
Kidney 2.9 1.3 0.7  0.5 11.7  7.0 109.3 3.3 0.11  0.08 1.7  0.6
75:25H MP Liver 38.0 10.8 4.5 1.1 18.0  1.7 425.0 55.0 0.04  0.01 13.9  1.0
Spleen ND 0.8 0.5 43.0  5.0 745.3 55.7 0.06  0.02 60.4  0.2
Kidney 4.3 0.4 1.2  0.5 24.3  3.7 221.7 30.7 0.11  0.02 1.6  0.1
a Cmax and AUC values were normalized to the doses of GEN administered (1.5 mg/kg of loaded GEN and three doses of 40 mg/kg every 2.5 h of free GEN).
b MP, microsphere.
c ND, the half-life could not be determined because over the time interval of the study, the GEN concentration in the spleen was maintained and did not vary.
TABLE 2. Protective effect of three doses of GEN-loaded microparticles against sublethal infection with Brucellamelitensis 16M
administered intraperitoneally
Treatment
Result for the following time after administration of last dosea:
1 wk 3 wk
Spleen wt (g) Log CFU/spleen Reduction(log) Spleen wt (g) Log CFU/spleen
Reduction
(log)
Untreated 0.87 0.08 6.85 0.17 0.00 0.93  0.11 6.73 0.18 0.00
Free GEN 0.86  0.05 6.77 0.12 0.08 0.83  0.26 6.77 0.12 0.04
502H empty MPb 0.80  0.05 6.83 0.16 0.02 1.04  0.14 6.87 0.30 0.13
75:25H empty MP 0.78  0.28 6.80 0.12 0.05 1.16  0.19 6.70 0.18 0.04
502H GEN MP 0.92  0.07 6.44 0.05 0.41** 1.12  0.44 6.28 0.09 0.45
75:25H GEN MP 0.87  0.16 6.13 0.08 0.72** 0.70  0.36 5.29 1.58 1.45**
a Groups of six mice each were infected intraperitoneally with B. melitensis 16 M (1  105 CFU/mouse). After 2 weeks, the animals received three doses of free or
encapsulated GEN (1.5 mg/kg). At 1 and 3 weeks after administration of the last dose, the animals were killed. **, P  0.01 (Mann-Whitney U test).
b MP, microsphere.
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aminoglycosides are highly stable and are not metabolized in
the liver. Because of their polar nature, they penetrate cells
very poorly, but once they are inside cells, their intracellular
retention is very high (28).
From a pharmacodynamic point of view, antibiotics are fre-
quently divided into two major groups: those that exhibit time-
dependent (concentration-independent) killing and reduced
persistent effects and those that exhibit a concentration-depen-
dent killing and prolonged persistent effects (4, 5, 9). There-
fore, for the second group of antibiotics, which includes the
aminoglycosides, the goal should be to maximize the drug
concentration. Interestingly, the concentrations of GEN in the
liver and the spleen were in the range of the in vitro MBC for
B. melitensis (14).
BALB/c mice were chronically infected with a virulent strain
of B. melitensis and treated with the selected GEN-containing
formulations. The results indicated that the treatment with
free GEN was ineffective, in agreement with the undetectable
levels of GEN in the liver and the spleen. Empty microspheres
did not produce any antibacterial effect. In contrast, both mi-
croparticle formulations significantly reduced the level of in-
fection in the spleen from 1 week after administration, and at
3 weeks after administration, 75:25H microspheres managed to
reduce the counts in the spleen more efficiently (1.45 logs) than
those made of 502H (0.45 log). These data agree with the
higher AUC and MRT in spleen shown by the former formu-
lation.
In conclusion, 75:25H microspheres were the most suitable
formulation for the treatment of brucellosis among the PLGA
micro- and nanoparticles studied. Nevertheless, GEN loading
improvement or the administration of more doses would be
required before the formulation could be used for the treat-
ment of human brucellosis.
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